US OTC Monograph Overhaul Like Makeover To Resemble Other FDA Drug Application Programs
Executive Summary
In draft guidance on format and content for OMORs, CDER framed recommendations by same model it’s used for guidances on other drug applications, common technical document for registration developed by the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use.
You may also be interested in...
House Health Subcommittee Members Question Dual Rx/OTC Status In FDA’s ACNU Proposal
Republicans Robert Latta and Dan Crenshaw and Democrat Debbie Dingell are members of House Energy and Commerce Committee’s Health Subcommittee, predominant source of legislation affecting FDA operations.
In US OTC Monograph Program, ‘FDR’ Spells Appealing FDA's Rejections Of Change Requests
Draft guidance adds “formal dispute resolution” to other terms becoming common in OTC drug sector since agency began overhaul of monograph drug program authorized in 2020. Others are OMOR, for OTC monograph order request, and OMUFA, for user fee program also authorized.
US Q1 Consumer Health Earnings Preview: Lifted By Welcome Changes, Or Slowed By Surprises?
An end to US COVID-19 PHE on 10 April doesn’t end inflationary pressure on prices for consumer packaged goods. OTC, supplements and personal care product firms could be reporting consumers during Q1 were going along with price increases, opting for less expensive options or buying less.